Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Dec 15, 2025
| Drug Name | Phase |
|---|---|
Aglatimagene besadenovec + valacyclovir | Phase 3 |
aglatimagene besadenovec | Phase 2 |
CAN-2409 | Phase 2 |
1 upcoming, 0 past
Primary completion for Aglatimagene besadenovec trial (NCT02446093) in Borderline Resectable Pancreatic Adenocarcinoma
Source